Genocea Appoints Jonathan Poole as Chief Financial Officer

  Genocea Appoints Jonathan Poole as Chief Financial Officer

Business Wire

CAMBRIDGE, Mass. -- April 7, 2014

Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical
company developing T cell-enabled vaccines and immunotherapies, today
announced the appointment of Jonathan Poole to the position of chief financial
officer. Mr. Poole joins Genocea from Shire plc (NASDAQ: SHPG).

Genocea Appoints Jonathan Poole as Chief Financial Officer (photo: Business
Wire)

Genocea Appoints Jonathan Poole as Chief Financial Officer (photo: Business
Wire)

“Jonathan’s broad experience in finance and strategic planning from Shire will
prove invaluable as we pursue our aim to harness T cells to develop
life-changing vaccines and immunotherapeutics,” said Chip Clark, president and
chief executive officer of Genocea. “We are pleased to welcome Jonathan to the
management team and look forward to his leadership.”

Prior to joining Genocea, Mr. Poole was senior vice president of finance for
pipeline and technical operations, leading finance support for Shire’s global
business development, R&D and technical operations activities. Mr. Poole
previously served for three years as divisional CFO of Shire HGT, Shire’s $1.5
billion rare disease division. He began his career in the UK in investment
banking at UBS Warburg and ING Barings and also worked as an investment
manager for Avanti Capital Plc, a UK private equity investment firm. Mr. Poole
has a MBA from London Business School and a BSc in biological sciences from
Durham University in the UK.

“Genocea’s unique and powerful ATLAS™ technology has the potential to
dramatically change the discovery and development of vaccines and
immunotherapies for patients suffering from or exposed to some of the most
challenging diseases we face,” said Jonathan Poole. “I am excited to join
Genocea at such an exciting time and look forward to helping the company
evolve and grow.”

About Genocea

Genocea is harnessing the power of T cell immunity to develop the next
generation of vaccines and immunotherapies. T cells are increasingly
recognized as a critical element of protective immune responses to a wide
range of diseases, but are difficult to target using traditional discovery
methods. Genocea is able to identify protective T cell antigens in humans
using ATLAS™, its proprietary technology platform, potentially enabling
vaccines and immunotherapies to address critical patient needs. Genocea’s
pipeline of novel clinical stage T cell-enabled product candidates includes
GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by
pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis,
malaria and cancer immunotherapy.

Forward Looking Statement

Statements herein relating to future business performance, conditions or
strategies and other financial and business matters, including expectations
regarding clinical developments, are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act. Genocea cautions that
these forward-looking statements are subject to numerous assumptions, risks
and uncertainties, which change over time. Factors that may cause actual
results to differ materially from the results discussed in the forward-looking
statements or historical experience include risks and uncertainties, including
Genocea’s ability to progress any product candidates in preclinical or
clinical trials; the scope, rate and progress of its preclinical studies and
clinical trials and other research and development activities; clinical trial
results; current results may not be predictive of future results; even if the
data from preclinical studies or clinical trials is positive, the product may
not prove to be safe and efficacious; Genocea’s ability to enter into future
collaborations with industry partners and the government and the terms, timing
and success of any such collaboration; the cost of filing, prosecuting,
defending and enforcing any patent claims and other intellectual property
rights; our ability to obtain rights to technology; competition for clinical
resources and patient enrollment from drug candidates in development by other
companies with greater resources and visibility; our ability to obtain
adequate financing in the future through product licensing, co-promotional
arrangements, public or private equity or debt financing or otherwise; general
business conditions; competition; business abilities and judgment of
personnel; and the availability of qualified personnel. Further information on
the factors and risks that could affect Genocea’s business, financial
conditions and results of operations is contained in Genocea’s filings with
the U.S. Securities and Exchange Commission, which are available at
www.sec.gov. These forward-looking statements speak only as of the date of
this press release and Genocea assumes no duty to update forward-looking
statements.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20140407005368/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50838788&lang=en

Contact:

Media Contact:
Linnden Communications
Michelle Linn, 508-362-3087
cell: 774-696-3803
Michelle@linndencom.com
or
Investor Contact:
Genocea Biosciences
Bob Farrell, 617-674-8261
Bob.Farrell@genocea.com
 
Press spacebar to pause and continue. Press esc to stop.